Adrebloc100 mg/10 ml

Adrebloc is an ultra-short-acting, cardioselective beta-1 adrenergic blocking agent given by intravenous (IV) infusion. Its evidence-based uses include:

• Established/approved use: Rapid control of ventricular rate in patients with supraventricular tachyarrhythmias, including atrial fibrillation and atrial flutter, in perioperative, postoperative, or other urgent/emergent circumstances.
• Established/approved use: Management of noncompensatory sinus tachycardia where the rapid heart rate requires urgent intervention on clinical judgment.
• Established/approved use: Short-term control of tachycardia and hypertension occurring during and immediately after surgery (perioperative tachycardia/hypertension), such as during induction and intubation, or in the immediate postoperative period.
• Guideline-supported/adjunct use: Emergency short-term rate/blood pressure control in hypertensive emergencies or aortic dissection, typically as part of combination therapy with other agents, in a monitored critical-care setting.
• Off-label use (used in specialist practice, not a primary labeled indication): Test-dosing to predict tolerance of longer-acting beta-blockers, and selected pediatric ICU tachyarrhythmia/hypertension management under specialist supervision.

Adrebloc is intended only for short-term, continuously monitored use in a hospital or critical-care setting.

Each formulation of Esmolol Hydrochloride is manufactured as a sterile solution for intravenous use. It is available as:

• A concentrated injection solution (for dilution before infusion) containing Esmolol Hydrochloride equivalent to a stated strength per mL (e.g., 10 mg/mL or 250 mg/mL concentrate).
• Premixed, ready-to-use infusion bags in dextrose solution at a standardized concentration (e.g., 10 mg/mL) for direct IV infusion.

Exact strengths and pack sizes vary by manufacturer; always check the product label of the specific brand dispensed.

Adrebloc is a synthetic, cardioselective (beta-1-selective) adrenergic receptor blocking agent with an extremely short duration of action, developed specifically for intravenous use in acute care settings. It is rapidly metabolized by esterases present in red blood cells, giving it a plasma half-life of approximately 9 minutes, so its effects begin and resolve quickly once the infusion is started or stopped.

Because of this rapid onset and offset, Adrebloc allows clinicians to titrate heart rate and blood pressure control minute-to-minute, and to stop the effect promptly if it is not tolerated, which makes it particularly useful during surgery, anesthesia, and other emergency situations requiring close hemodynamic control.

Adrebloc belongs to the therapeutic class of cardioselective (beta-1-selective) adrenergic blocking agents (beta-blockers), specifically an ultra-short-acting parenteral beta-blocker used in acute cardiovascular care.

Esmolol Hydrochloride selectively blocks beta-1 adrenergic receptors, which are predominantly located in cardiac tissue, with relatively little effect on beta-2 receptors (found in bronchial and vascular smooth muscle) at usual therapeutic doses. By blocking beta-1 receptors, it:

• Reduces heart rate (negative chronotropic effect)
• Reduces the force of myocardial contraction (negative inotropic effect)
• Slows conduction through the atrioventricular (AV) node
• Reduces myocardial oxygen demand

Esmolol Hydrochloride has no significant intrinsic sympathomimetic activity or membrane-stabilizing activity at clinical doses. It is rapidly hydrolyzed by esterases in red blood cell cytosol (not by plasma cholinesterase), producing an inactive acid metabolite and methanol (in clinically insignificant amounts). Onset of beta-blockade occurs within minutes of starting an infusion, and effects resolve within approximately 10-20 minutes of stopping it, because of its very short elimination half-life (~9 minutes).

Adrebloc is for intravenous use only and must never be given by any other route (e.g., not intramuscular, not oral, not subcutaneous).

• The concentrated injection must be diluted per manufacturer instructions before infusion (see Reconstitution); premixed infusion bags can be used directly.
• Administer via a controlled infusion pump for accurate rate titration.
• Administer preferably into a large vein to reduce the risk of infusion-site reactions; avoid small veins or "butterfly" catheters.
• Continuous ECG, heart rate, and blood pressure monitoring is required throughout the infusion.
• Do not mix with sodium bicarbonate solutions; check compatibility before co-administering other IV medications in the same line.
• Discontinuation should generally be gradual/tapered when clinically feasible after prolonged use, rather than abrupt, to reduce the risk of rebound tachycardia or hypertension (see Precautions and Warnings).

Clinically significant interactions with Adrebloc include:

• Calcium channel blockers (e.g., verapamil, diltiazem): Concurrent IV use with Adrebloc can produce additive negative effects on heart rate, AV conduction, and contractility, increasing the risk of severe bradycardia, high-degree AV block, and hypotension; combine with caution and close monitoring.
• Digoxin: Adrebloc can increase digoxin plasma concentrations; digoxin levels and signs of toxicity should be monitored when co-administered.
• Catecholamine-depleting drugs (e.g., reserpine) or other antihypertensives/negative chronotropes: May have additive hypotensive and bradycardic effects with Adrebloc.
• Succinylcholine: Adrebloc may prolong the neuromuscular blocking effect of succinylcholine when given concurrently during anesthesia.
• Inhalational anesthetics: Additive myocardial depressant and hypotensive effects are possible when Adrebloc is used with certain general anesthetics.
• Insulin and oral hypoglycemic agents: Adrebloc, like other beta-blockers, may mask the tachycardia that is a warning sign of hypoglycemia; blood glucose should be monitored more closely in diabetic patients.

Always inform the treating physician or anesthesiologist of all other medications being used before Adrebloc is administered.

Side effects of Adrebloc are generally dose-related and resolve quickly after the infusion is stopped or the rate is reduced, given its very short half-life.

• Very common/common: Hypotension (the most frequently reported effect), injection/infusion-site reactions (pain, redness, induration, or, rarely, skin necrosis with extravasation), dizziness, somnolence, headache, nausea, and sweating.
• Common cardiac effects: Bradycardia, and less commonly first-degree AV block or other conduction disturbances.
• Less common: Confusion, agitation, or altered mental status (especially at higher infusion rates), bronchospasm in susceptible individuals, flushing, and mild elevations in liver enzymes.
• Rare/serious: Severe bradycardia, high-degree AV block, severe hypotension, or bronchospasm requiring dose reduction or discontinuation (see Contraindications and Precautions and Warnings).

Report any unusual or severe symptoms to the treating medical team immediately, as Adrebloc is used under continuous monitoring.

Pregnancy: Data on the use of Adrebloc in human pregnancy are limited. As with other beta-blockers, use during pregnancy has been associated in some reports with fetal/neonatal effects such as bradycardia, hypotension, and hypoglycemia when used near delivery. Adrebloc should be used during pregnancy only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus; use only under close physician supervision, generally reserved for situations where maternal cardiovascular stabilization is essential.

Lactation: It is not established whether Adrebloc is excreted in human breast milk. Because of its very short half-life, systemic exposure to the infant is expected to be minimal, but caution is advised; a physician should weigh the benefits of maternal treatment against any potential risk to the breastfeeding infant, and the infant should be monitored if breastfeeding continues during or shortly after treatment.

In all cases, use of Adrebloc in pregnant or breastfeeding women should be directed and monitored by a physician.

• Hypotension and bradycardia: Adrebloc commonly causes dose-related hypotension and bradycardia; monitor blood pressure and heart rate continuously and reduce or stop the infusion if severe (see Side Effects).
• Abrupt discontinuation: Stopping Adrebloc suddenly after prolonged infusion may be associated with rebound tachycardia, hypertension, or worsening of underlying ischemic heart disease; taper when clinically feasible and transition to an oral beta-blocker under supervision if long-term therapy is planned.
• Bronchospastic disease (asthma/COPD): Although cardioselective, Adrebloc can still provoke bronchospasm, particularly at higher infusion rates; use with caution and have bronchodilator therapy available in patients with reactive airway disease.
• Diabetes mellitus: Adrebloc may mask signs of hypoglycemia such as tachycardia; monitor blood glucose more closely in diabetic patients.
• Heart failure/reduced cardiac function: Use with caution in patients with compensated heart failure or reduced left ventricular function, as beta-blockade can further reduce contractility.
• Extravasation: Infiltration of the infusion site can cause tissue irritation or, rarely, skin necrosis; use a well-secured, preferably large-vein IV line and check the site regularly.
• Peripheral vascular disease: Beta-blockade may aggravate symptoms of peripheral arterial insufficiency.
• Use only in a monitored setting: Adrebloc should be administered only where continuous ECG, blood pressure, and clinical monitoring, and resuscitation facilities, are immediately available.

Overdose or excessively rapid administration of Adrebloc can cause severe bradycardia, high-degree AV block, marked hypotension, worsening heart failure, bronchospasm, or loss of consciousness.

Because of its very short half-life, most effects of overdose resolve within minutes of stopping the infusion; however, any suspected overdose is a medical emergency. Stop the infusion immediately and seek immediate medical attention (contact emergency services or a poison control center). Supportive treatment in a monitored/critical-care setting (e.g., IV fluids, vasopressors, atropine, temporary pacing, or other supportive measures as directed by a physician) may be required. Do not attempt to manage a suspected overdose at home, since Adrebloc is administered only in a hospital/clinical setting.

Store at room temperature (below 30°C), away from light and moisture. Do not freeze. Keep out of reach of children. Store and dilute strictly according to the specific product's labeling, and use diluted infusion solutions within the time frame specified by the manufacturer.

• Elderly: No specific dose adjustment is mandated, but elderly patients may be more sensitive to the hypotensive and bradycardic effects of Adrebloc; use conservative initial rates and monitor closely.
• Renal impairment: Adrebloc's acid metabolite is renally cleared; while no formal dose adjustment is established, patients with renal impairment should be monitored closely, especially with prolonged infusions.
• Hepatic impairment: No specific dosage adjustment is established, since hepatic metabolism is not the primary elimination pathway.
• Pediatric patients: Safety and efficacy have not been formally established in children; see Pediatric Uses.
• Pregnant/breastfeeding women: See Pregnancy and Lactation.

Adrebloc is intended strictly for short-term use, generally limited to the duration of the acute event, surgical procedure, or period of hemodynamic instability being managed (commonly minutes to no more than about 24-48 hours of continuous infusion). It is not intended for chronic or long-term maintenance therapy. If ongoing beta-blocker therapy is needed beyond the acute period, the treating physician will typically transition the patient to an appropriate oral beta-blocker.

The concentrated injection form of Adrebloc (e.g., double-strength concentrate ampoule/vial) is not for direct IV injection and must be diluted before use. Typical preparation:

• Dilute the concentrate with a compatible IV fluid (such as 5% dextrose injection, 0.9% sodium chloride, or other manufacturer-specified diluent) to achieve the standard infusion concentration (commonly 10 mg/mL) as directed on the product label.
• Mix thoroughly and inspect visually for particulate matter or discoloration before use; discard if present.
• Premixed, ready-to-use infusion bags do not require further dilution and should be used as supplied.

Always follow the specific dilution instructions on the manufacturer's label for the exact product dispensed.

Esmolol Hydrochloride is classified as a cardioselective (beta-1-selective) adrenergic receptor blocking agent (a beta-blocker), specifically an ultra-short-acting, intravenously administered agent used in acute cardiac care and anesthesia.

Esmolol Hydrochloride works by selectively and competitively blocking beta-1 adrenergic receptors, which are found mainly in cardiac muscle and the conduction system of the heart. By blocking the effects of circulating catecholamines (such as adrenaline and noradrenaline) at these receptors, Esmolol Hydrochloride reduces heart rate, slows AV nodal conduction, and decreases the force of cardiac contraction, thereby lowering myocardial oxygen demand and helping to control fast heart rates and, indirectly, blood pressure. Its action begins within minutes and dissipates quickly (half-life approximately 9 minutes) because it is rapidly broken down by esterase enzymes present in red blood cells, allowing precise, controllable titration of effect.

C

Adrebloc does not have a formally established pediatric indication in official product labeling, and safety and efficacy in pediatric patients have not been definitively established. Despite this, Adrebloc is sometimes used off-label by pediatric cardiology/critical-care and anesthesia specialists for short-term control of supraventricular tachyarrhythmia or perioperative hypertension/tachycardia in children, including in neonatal and pediatric intensive care settings, based on published clinical experience.

Any use of Adrebloc in infants or children should be undertaken only by a pediatric specialist experienced in its use, with continuous cardiac and hemodynamic monitoring, and individualized, weight-based dosing.